SOL Capital Management CO Reduces Holdings in SPDR S&P Biotech ETF $XBI

SOL Capital Management CO trimmed its holdings in shares of SPDR S&P Biotech ETF (NYSEARCA:XBI) by 24.7% in the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 16,565 shares of the exchange traded fund’s stock after selling 5,425 shares during the quarter. SOL Capital Management CO’s holdings in SPDR S&P Biotech ETF were worth $1,660,000 at the end of the most recent quarter.

Other institutional investors have also added to or reduced their stakes in the company. Ameriprise Financial Inc. grew its stake in shares of SPDR S&P Biotech ETF by 123.0% during the 2nd quarter. Ameriprise Financial Inc. now owns 872,796 shares of the exchange traded fund’s stock valued at $72,542,000 after acquiring an additional 481,408 shares during the period. Meitav Investment House Ltd. lifted its holdings in SPDR S&P Biotech ETF by 2,199.6% during the second quarter. Meitav Investment House Ltd. now owns 400,454 shares of the exchange traded fund’s stock valued at $33,229,000 after purchasing an additional 383,040 shares in the last quarter. JPMorgan Chase & Co. lifted its holdings in SPDR S&P Biotech ETF by 2.6% during the second quarter. JPMorgan Chase & Co. now owns 10,638,105 shares of the exchange traded fund’s stock valued at $882,218,000 after purchasing an additional 268,399 shares in the last quarter. Marshall Wace LLP boosted its position in shares of SPDR S&P Biotech ETF by 102.3% in the second quarter. Marshall Wace LLP now owns 4,023 shares of the exchange traded fund’s stock worth $334,000 after purchasing an additional 179,029 shares during the period. Finally, Clal Insurance Enterprises Holdings Ltd increased its stake in shares of SPDR S&P Biotech ETF by 68.5% in the second quarter. Clal Insurance Enterprises Holdings Ltd now owns 428,000 shares of the exchange traded fund’s stock worth $35,494,000 after purchasing an additional 174,000 shares in the last quarter.

SPDR S&P Biotech ETF Price Performance

Shares of XBI stock opened at $124.18 on Friday. SPDR S&P Biotech ETF has a one year low of $66.66 and a one year high of $129.12. The company’s fifty day moving average price is $121.14 and its 200-day moving average price is $104.39. The company has a market capitalization of $8.22 billion, a price-to-earnings ratio of 11.47 and a beta of 0.93.

SPDR S&P Biotech ETF Profile

SPDR S&P Biotech ETF (the Fund) seeks to closely match the returns and characteristics of the S&P Biotechnology Select Industry Index. The S&P Biotechnology Select Industry Index represents the biotechnology sub-industry portion of the S&P Total Markets Index. The S&P TMI tracks all the United States common stocks listed on the New York Stock Exchange, American Stock Exchange, National Association of Securities Dealers Automated Quotation (NASDAQ) National Market and NASDAQ Small Cap exchanges. The Biotech Index is a modified equal weight index.